Merck & Co., Inc. (NYSE:MRK) Releases Earnings Results, Beats Estimates By $0.03 EPS

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings results on Thursday. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.31) by $0.03, FiscalAI reports. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.91 billion. During the same quarter in the previous year, the firm earned $2.22 EPS. Merck & Co., Inc.’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. updated its FY 2026 guidance to 5.040-5.160 EPS.

Here are the key takeaways from Merck & Co., Inc.’s conference call:

• Merck reported Q1 revenue of $16.3 billion (up 5%) and has narrowed and raised its 2026 non‑GAAP guidance to $65.8–$67.0 billion revenue and $5.04–$5.16 EPS, citing continued oncology, Animal Health, and new‑product momentum.
• A $9 billion one‑time acquisition‑related charge for Sedera drove a GAAP pre‑tax loss and produced a reported loss of $1.28/share this quarter, including a $3.62/share hit from the charge and an unusual tax rate impact (‑43.5%).
• Meaningful pipeline and regulatory progress — FDA approval of the once‑daily two‑drug HIV regimen Edvinso (doravirine+islatravir), priority review for Ifinatamab deruxtecan in extensive‑stage SCLC (PDUFA Oct 10), and upcoming PDUFA dates for Keytruda+Padcev and WELIREG combinations.
• Commercial strength and new launches: Keytruda family sales rose to $8.0 billion (+8%) with KEYTRUDA QLEX early sales of $128 million and permanent J‑code, while Animal Health delivered mid‑single‑digit growth and new product launches (e.g., Numelvy) support long‑term growth.
• Proposed acquisition of Terns (TERN‑701) targets a high‑value hematology opportunity with multibillion upside but will create a near‑term headwind — ~$5.8 billion one‑time R&D charge (~$2.35/share) and ~‑$0.12 EPS drag this year — management frames it as science‑led BD to strengthen the pipeline.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK traded down $1.62 during mid-day trading on Thursday, hitting $109.33. 17,085,152 shares of the stock traded hands, compared to its average volume of 8,626,114. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $125.14. The company has a market cap of $270.03 billion, a PE ratio of 15.02, a price-to-earnings-growth ratio of 2.25 and a beta of 0.26. The firm has a 50 day simple moving average of $117.69 and a two-hundred day simple moving average of $107.39.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results and product momentum: Merck beat Q1 revenue and adjusted EPS expectations, driven by continued Keytruda demand and contributions from newer launches (Winrevair reported at ~$525M), which underpin near‑term revenue growth. Merck Sales Beat As Winrevair Hits $525 Million
• Positive Sentiment: Management raised adjusted EPS guidance and emphasized oncology strength: Merck narrowed its 2026 guidance range but lifted its profit outlook on stronger Keytruda and new product trends, a positive for earnings power even as revenue bands were tightened. Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
• Positive Sentiment: Clinical pipeline progress: Merck dosed the first patient in Phase 3 studies of enpatoran for lupus skin manifestations — a near‑term clinical milestone that could add long‑term pipeline value if successful. Merck Announces First Dose in Phase 3 Study with Enpatoran
• Neutral Sentiment: Calls and disclosures available: The full Q1 earnings call transcript and the investor slide deck are posted for deeper review of sales mix, margin drivers and forward guidance assumptions. Q1 2026 Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Minor analyst estimate moves: Some shops trimmed FY forecasts modestly (e.g., Erste’s slight EPS tweak), indicating traders are tweaking models but not overhauling consensus. MRK Q1 Earnings & Sales Beat; 2026 Sales View Tightened
• Negative Sentiment: One‑time acquisition charge produced a GAAP loss: Merck reported a quarterly loss driven by a Cidara‑related acquisition charge, which suppresses headline earnings and can weigh on near‑term sentiment. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Tighter revenue guidance and mixed product trends: Management narrowed the sales range for 2026 and flagged mixed growth among some newer and legacy products, which leaves upside constrained and raises uncertainty about sustained top‑line acceleration. Merck Q1 earnings beat; 2026 guidance narrowed
• Negative Sentiment: Market concerns about future sales erosion: Commentary and coverage highlighted risks from expected declines in certain legacy drugs (HPV vaccine, diabetes medicine) and the company’s efforts to offset those losses, which contributes to investor caution. Merck Stock Falls After Earnings

Analyst Upgrades and Downgrades

MRK has been the subject of a number of research analyst reports. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a report on Friday, February 13th. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. UBS Group raised their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, TD Cowen raised their price objective on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $128.47.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the company’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $121.87, for a total value of $1,828,050.00. Following the sale, the insider owned 21,197 shares in the company, valued at approximately $2,583,278.39. The trade was a 41.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the completion of the sale, the chief marketing officer owned 70,615 shares in the company, valued at $8,361,522.15. This trade represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 320,176 shares of company stock worth $38,281,735 over the last 90 days. 0.17% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Institutional investors have recently made changes to their positions in the stock. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $26,000. IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $31,000. Safe Harbor Fiduciary LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $32,000. Gilpin Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $32,000. Finally, Wealth Watch Advisors INC bought a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at about $34,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.